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Abstract: In this study, we determined whether cisplatin can induce epithelial-mesenchymal transition (EMT) via the activa-
tion of Sonic hedgehog (Shh) or glioma-associated antigen-1 (Gli1) signaling pathway in mouse Hertwig’s epithelial root 
sheath (HERS) cells using a genetic knockdown approach. HERS cells treated with a low concentration of cisplatin (0.5 
µM) for 24 h showed no reduction in the cell viability; however, there was a significant increase in the percentages of nu-
clear staining with γH2AX as compared to that with untreated control cells, indicating that 0.5 µM cisplatin induces DNA 
damage. Further, 0.5-µM cisplatin-treated cells provided an induction of EMT, showing decreased and increased expression 
of epithelial and mesenchymal markers, respectively. Enhancement in the EMT activity in cisplatin-treated HERS cells was 
correlated with increased expression of Shh and accelerated translocation and accumulation of Gli1 expression into the nu-
cleus. The RNA interference-mediated silencing of Gli1 suppressed the acceleration of EMT in cisplatin-treated HERS 
cells; this was confirmed by no down-regulation or up-regelation in the expression of E-cadherin and vimentin, respectively, 
along with no increased expression of Snail expression. These findings suggest that the activation of Shh/Gli1 signaling 
pathway may be required for the enhancement of EMT in cisplatin-treated HERS cells.
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Introduction
Chemotherapeutic drugs are widely used and are effective in the 
treatment of pediatric cancers. Among many chemotherapeutic drugs, 
cisplatin, one of major platinum compounds, currently serve as the first 
line chemotherapy in the treatment of pediatric cancers, such as neuro-
blastoma, germ-cell tumors, osteosarcoma, retinoblastoma, hepatoblas-
toma, brain tumors, and relapsed and refractory lymphomas1). Cisplatin 
forms DNA-protein cross-links, causing breakage of DNA strands in 
cancer cells, to exert cytotoxic effects and trigger apoptosis in these 
cells2). Chemotherapy-induced DNA damage may provide some pallia-
tion; however, it is often associated with substantial treatment-related 
toxic effects.
Recent strong evidence supports an association between chemother-
apy and dental anomalies. In particular, children who receive chemo-
therapy before the age of 5 y may have a high risk of extensive damage 
to their dentition, indicated by the development of conditions, such as 
hypodontia, microdontia, enamel hypoplasia, dental caries, and atypical 
crown or root formation3, 4). In cases of arrested root development, short 
V-shaped roots and early closure of the apex are relatively common 
findings5). Root formation causes an overall increase in the tooth length 
to accompany intraosseous eruption during the process of emergence. 
Therefore, atypical root formation may cause disturbances in tooth erup-
tion that severely impact the oral health quality of life in children re-
ceiving long-term chemotherapy.
Root and cementum formation are controlled by Hertwig’s epithelial 
root sheath (HERS). The HERS, originating from an elongated apical 
region of the enamel organ, is composed of a bilayer epithelial structure 
between the dental papilla and dental follicle6); it grows apically and 
guides root formation, resulting in the determination of the size, shape, 
and number of the tooth’s root7). Among the fate of HERS nearing com-
pletion of root formation, an induction of epithelial-mesenchymal tran-
sition (EMT) is responsible for participation in the cementum and perio-
dontal ligament formation8, 9). Our recent report suggests that impaired 
root formation induced by chemotherapy may result in early closure of 
apex via induced EMT of HERS cells10).
The EMT provides depolarization of the epithelial cells; loss of their 
cell-cell contacts; and gain of an elongated, fibroblast-like morphology. 
Functional implications of EMT include enhanced migratory capacity, 
invasiveness, elevated resistance to apoptosis, and substantially in-
creased production of extracellular matrix components11). In in vitro ex-
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periments, cells treated with transforming growth factor β1 (TGF-β1) 
can show the induction of marked EMT characteristics11, 12). A previous 
study has demonstrated that TGF-β can induce EMT in HERS cell13). 
The EMT process is regulated in part by Sonic hedgehog (Shh) signal-
ing that corresponds to several biological processes in normal embryon-
ic development and adult tissue homeostasis6). Once Shh binds to 
Patched (Ptch), an inhibition of a signal transducer Smoothened (Smo) 
is relieved, leading to the translocation of Gli1 proteins into the nucleus 
and the activation of Shh genes expressions14). Activation of the Shh sig-
naling pathway, including nuclear translocation of Gli1 can provide in-
creased expression of snail, a major target of the Shh signaling pathway, 
as well as regulate EMT and fibroblast motility15). Although few studies 
have discussed the possibility of chemotherapy-induced EMT10, 16), 
whether cisplatin induces EMT in HERS cells remains unclear.
To the best of our knowledge, there has been no systematic study of 
the possible mechanisms of cisplatin that may induce EMT in HERS 
cells. Our previous study suggested that chemotherapy-induced EMT 
may provide the impaired root formation via an early closure of the 
apex10). In this study, we examined whether cisplatin could trigger EMT 
in HERS cells via the Shh/Gli1 signaling pathway.
Materials and Methods
Cells
The HERS cell line, HERS01a, was previously established17). HER-
S01a cells were maintained in Dulbecco’s Modified Eagle Medium: Nu-
trient Mixture F-12 (Fujifilm Wako Pure Chemical Corporation, Osaka, 
Japan) supplemented with B12 ((Invitrogen, Carlsbad, CA, USA), fibro-
blast growth factor-2 (FGF2, 10 ng/ml, Fibroblast Spray, Kakei Pharma-
ceutical Co., Ltd., Tokyo, Japan), epidermal growth factor (EGF, 10 ng/
ml, Pepro Tech, Rocky Hill, NJ, USA), and penicillin-streptomycin (100 
U/ml) in a humidified atmosphere of 5% CO2 and 37°C. Upon reaching 
sub confluence, the cells were treated with medium containing various 
concentration of cisplatin (0, 0.5, 1.0, 5.0, and 10 µM) for 24 h. Further-
more, we also examined the effect of TGF-β on the induction of EMT in 
the HERS cells. The cells were stimulated with medium containing 10 
ng/ml TGF-β for 24 h. 
Cell viability assay
HERS cells were seeded in 96-well plates with 100 µl of medium at 
a density of 1 × 104 cells/ml; they were incubated at 37°C overnight to 
allow the adherent cells to attach to the wells. The cultured cells were 
then incubated with cisplatin (0–10 µM) for 24 h. Thereafter, 10 µl cell 
counting kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan) was 
added to each well, and the cultured cells were incubated at 37°C for 4 
h. After incubation, the amount of formazan dye generated via cellular 
dehydrogenase activity was measured by absorbance at 480 nm as the 
detection wavelength and at 650 nm as the reference wavelength using a 
plate reader (Multiskan JX, Labsystems Oy, Helsinki, Finland).
Western blot analysis
The cells were lysed in cell lysis buffer (Cell Signaling Technology, 
Inc., Danvers, MA, USA) containing a 1x Protease/Phosphatase Inhibi-
tor Cocktail (Cell Signaling Technology). The protein content was 
measured using a protein assay kit (Pierce, Hercules, CA, USA). Protein 
samples, with a protein marker (Precision Plus Protein Western C Stand-
ard; Bio-Rad Laboratories, Inc., Richmond, CA, USA), were separated 
on 12% Mini-Protean TGX gels (Bio-Rad) for 30 min at 200 V. The 
separated gels were then transferred to a polyvinylidene fluoride mem-
brane for 7 min with the Trans-Blot Turbo Transfer system (Bio-Rad) 
using Trans-Blot Transfer Packs. Western blots were processed on the 
iBind Western System (Life Technologies, Carlsbad, CA, USA) with 
anti-b-actin (Bio-Rad), anti-E-Cadherin (1:1,000; Cell Signaling Tech-
nology), anti-CK14 (1:1,000; Cell Signaling Technology), anti-vimentin 
(1:1,000; Cell Signaling Technology), anti-N-cadherin (1:1,000; Abcam, 
Cambridge, UK), sonic hedgehog (Shh, 1:1,000; Cell Signaling Tech-
nology), and horseradish peroxidase-conjugated anti-rabbit or -mouse 
secondary antibodies (Bio-Rad). The protein bands were developed with 
an enhanced chemiluminescence system (SignalFire Plus ECL Reagent, 
Cell Signaling Technology). The band density was quantified using the 
NIH ImageJ software.
Immunocytochemical analysis
The HERS cells were cultured on the 10-well glass slides and fixed 
with 4% paraformaldehyde for 10 min and washed in 0.3% Triton-X in 
phosphate buffered saline (PBS) for 10 min. The cells were then incu-
bated with anti-E-cadherin (1:200; Cell Signaling Technology), anti-vi-
mentin (1:200; Cell Signaling Technology), anti-glioma-associated anti-
gen-1 (Gli1, 1:100; Cell Signaling Technology), anti-snail (1:100; Cell 
Signaling Technology), and anti-γH2AX (1:100; Dojindo Laboratories), 
at 4°C overnight. After washing with PBS, the cells were incubated with 
anti-rabbit IgG or anti-mouse IgG conjugated with Alexa Fluor 488 or 
556 (1:400; Molecular Probe, Eugene, OR, USA) at room temperature 
for 45 min. In order to visualize the nuclei, the cells were counterstained 
with 4, 6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Inc., 
Burlingame, CA, USA). The percentages of positive cells were estimat-
ed under the ×40 objective lens of a fluorescence microscope at 5 differ-
ent sites of each slide glass.
Blockade of the Shh/Gli1 signaling pathway
Small-interfering RNA (siRNA) for Gli1 was used to inhibit the 
Shh/Gli1 pathway. The HERS01a cells were seeded in 24-well plates at 
a density of 5 × 104 cells/well and were transfected with siRNA for Gli1 
(5’-AACUCCACAGGCAUACAGGAU-3’) and a negative control siR-
NA (NC siRNA: 5’-AACGUACGCGGA AUACAACGA-3’) were pur-
chased from Hokkaido System Science Co., Ltd. (Sapporo, Japan)18). 
siRNA was introduced into the cells using HilyMax (Dojindo Laborato-
ries). Twenty-four hours thereafter, the cells were stimulated with or 
without cisplatin. After treatment with or without cisplatin for 24 h, 
those cells were stained with antibodies for downstream target factors in 
the Shh/Gli1 signaling pathway. All the siRNA experiments were per-
formed in triplicate.
Statistical analyses
All the statistical analyses were performed with EZR (Saitama Med-
ical Center, Jichi Medical University, Saitama, Japan), a graphical user 
interface for R (The R Foundation for Statistical Computing, Vienna, 
Austria). More precisely, it is a modified version of the R commander 
designed to add statistical functions frequently used in biostatistics. The 
analyses were performed using one-way analysis of variance and Tukey 
multiple comparison test to determine the statistical differences among 
the samples. Data are presented as the mean ± standard deviation (SD) 
values, and p values < 0.05 were considered to indicate statistical signif-
icance.
Results
Low concentration of cisplatin treatment does not decrease the cell vi-
ability
Cell viability was detected using the CCK-8 assay. The HERS cells 
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were treated with 0 (as a control), 0.5, 1.0, 5.0, and 10 µM cisplatin for 
24 h to estimate the cell viability. As shown in Fig. 1, low-concentration 
treatment groups (0.5 and 1.0 µM) showed no significant reduction in 
the cell viability as compared to the control group (p > 0.2), while the 
other groups (5.0 µM and 10 µM) notably reduced the viability of the 
HERS cells (p < 0.001) in a dose-dependent manner.
Low concentration of cisplatin treatment can induce DNA damage in 
HERS cells
Cisplatin kills cancer cells by damaging their DNA. During DNA 
damage by stimulus, γH2AX is produced via the phosphorylation of 
H2AX. We performed immunocytochemical detection of nuclear 
γH2AX to determine whether cisplatin can induce DNA damage in the 
HERS cells (Fig. 2A). Most untreated HERS cells showed only few 
positive cells (14.5% ± 2.8%). Promotion of nuclear γH2AX staining 
was gradually increased in the HERS cells treated with 0.5 µM and 1.0 
µM cisplatin (43.2% ± 12.0% and 57.2% ± 5.4%, respectively). There 
was a significant difference in the proportion of nuclear staining be-
tween untreated (Ctr) and 0.5-µM cisplatin-treated cells (p = 0.012) (Fig. 
2B). These findings indicate that 0.5 µM cisplatin treatment does not re-
duce the cell viability significantly; however, this concentration of cis-
platin can induce DNA damage in the HERS cells. Thus, we selected 
this concentration as the effective concentration for performing further 
research.
Low concentration of cisplatin can induce EMT in the HERS cells
In order to investigate whether cisplatin treatment induces EMT in 
the HERS cells, we first examined that EMT of HERS cells was induced 
via stimulation of TGF-β, known as an EMT inducer. After stimulation 
by TGF-β, the cells acquired an elongated and mesenchymal-like mor-
phology with loss of cell-cell contact, while the control cells remained a 
cobblestone morphology as epithelial characteristics (Fig. 3A). Western 
blot analysis showed that the protein level of both, E-cadherin and 
CK14 was decreased. In contrast, the cells treated with TGF-β showed 
increased expression of N-cadherin, as compared to that of the controls 
(Fig. 3B). Intensity of vimentin expression in TGF-β-treated cells was 
similar to that of the control cells (Fig. 3B).
Then, we examined whether low concentration of cisplatin (0.5 µM 
and 1.0 µM) could induce a morphological change characteristic of 
EMT. The HERS cells without cisplatin exhibited a cobblestone-epithe-
lial morphology. However, the cells stimulated by cisplatin showed a 
mesenchymal-like morphology with an elongated shape and loss of cell-
cell contact (Fig. 3C). In the western blot analysis, downregulated ex-
pression of epithelial markers (E-cadherin and CK14) in the cells treated 
with 0.5 µM cisplatin was noted. Cisplatin-treated cells showed increased 
expression of N-cadherin in a dose-dependent manner, as compared to the 
control cells (Fig. 3D). Vimentin expression was increased in the cells 
treated with 0.5 µM cisplatin, whereas in the 1.0 µM cisplatin-treated 
cells vimentin expression was suppressed (Fig. 3D). These findings indi-
cated that cisplatin-induced EMT characteristics in the HERS cells.
Figure 1. Effect of cisplatin on cell viability. Cell viability of the HERS 
cells treated with 0 (Ctr, control)–10 µM cisplatin for 24 h using the Cell 
Counting Kit-8 assay. There was no significant difference in the groups of 
gray columns jointed to horizontal bar. *, significant difference at p < 0.001 
compared with 5- and 10–µM cisplatin-treated groups.
Figure 2. Increased promotion of cisplatin-treated HERS cells with nuclear γH2AX staining. HERS cells treated with (0.5 and 1.0 µM) and with-
out cisplatin were labeled for γH2AX (red). The nuclei were stained with DAPI (blue). A: Representative immunofluorescence images of nuclear 
γH2AX staining. Bars = 20 µm. B: Proportion (%) of HERS cells with nuclear γH2AX staining as mean ± standard deviation (SD) values 
(n = 3). *, **, Significant differences at p < 0.05, P < 0.001, respectively, compared with Ctr.
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Figure 4. Shh/Gli1 pathway in the HERS cells treated with 0.5 µM cisplatin. A: Representative western blot using antibody against Shh. B and C: 
Immunofluorescence images of nuclear translocation of Gli1 (B; red) and cytoplasmic staining with snail (C; green) in HERS cells treated with 
or without cisplatin. Nuclei were stained with DAPI. The graphs show quantified data of the percentages of positive cells stained with anti-Gli1 
and snail as mean ± standard deviation (SD) (n = 3). *, significant difference at p < 0.001 with Ctr. Ctr, control; NC siRNA, negative control 
siRNA. Scale bars: 20 µm.
Figure 3. TGF-β and cisplatin induces EMT in the HERS cells. A: Representative phase contrast images of a morphological phenotype in the 
HERS cells treated with or without TGF-β. B: HERS cells were stimulated with TGF-β (10 ng/ml) or in complete medium for 24 h. Representa-
tive western blots using antibodies against N-cadherin, vimentin, E-cadherin, and CK14. C: Representative phase contrast images of EMT induc-
tion in HERS cells treated with or without cisplatin. D: The HERS cells were treated with cisplatin (0.5 and 1.0 µM) or in complete medium for 
24 h. Representative western blots using antibodies against N-cadherin, vimentin, E-cadherin, and CK14. Ctr, control. Scale bars: 20 µm.
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In the HERS cells, 0.5 µM cisplatin induces enhancement of the Shh/
Gli1 pathway
We examined the expressions of Shh and Gli1 in HERS cells treated 
with or without 0.5 µM cisplatin to investigate whether Shh/Gli1 path-
way is related to cisplatin-induced EMT. As indicated by the results of 
the western blotting analysis (Fig. 4A), the cells exposed to 0.5 µM cis-
platin for 24 h showed increased Shh expression as compared to that in 
the control cells. The nuclear translocation of Gli1 is a key inducer of 
EMT19). Then, we examined the immunocytochemical detection of Gli1 
in HERS cells treated with or without 0.5 µM cisplatin. The nuclear lo-
calization and accumulation of Gli1 was observed in HERS cells treated 
with 0.5 µM cisplatin (Fig. 4B). The percentages of nuclear positive 
cells were much higher in the 0.5-µM cisplatin-treated cells than in the 
control cells (90.8% ± 2.2% vs. 10.9% ± 1.4%, p < 0.001; Fig. 4B). Fur-
thermore, snail is a well-known target of the Shh/Gli1 signaling18). We 
finally performed immunocytochemical detection of snail in HERS cells 
treated with or without 0.5 µM cisplatin. Cisplatin-treated cells showed 
cytoplasmic reaction in snail, while no staining was observed in the un-
treated cells (Fig. 4C). The percentages of snail-positive cells were 
higher in the 0.5-µM cisplatin-treated cells than in the control cells 
(71.8% ± 9.2% vs. 6.0% ± 4.0%, p < 0.001; Fig. 4C). These results sug-
gest that cisplatin-induced EMT may be partially regulated by the Shh/
Gli1 signaling pathway.
Suppression of Gli1 signaling reduces cisplatin-induced EMT in 
HERS cells
In order to examine whether Gli1 signaling mediates 0.5 µM cispla-
tin-induced EMT, siRNA was used for silencing Gli1. Transfection of 
Gli1 siRNA into the HERS cells attenuated immunocytochemical ex-
pression of Gli1 protein in these cells (Fig. 5A). The transfected cells 
were then treated with 0.5 µM cisplatin. Compared to transfection with 
a negative control siRNA, immunofluorescence images and semi-quan-
tified graphs of the percentage of positive cells showed that transfection 
with Gli1-specific siRNA significantly decreased the EMT process, as 
demonstrated by the lower expression of snail and vimentin and the in-
creased expression of E-cadherin (Fig. 5A, B). These findings suggest 
that inhibition of Shh/Gli1 signaling effectively suppressed the EMT 
process in vitro.
Figure 5. Reduction of cisplatin-mediated EMT in the HERS cells by blockade of Gli1 signaling. The cells were stimulated with 0.5 µM cisplatin 
in the presence of a Gli1 siRNA or NC siRNA as indicated. A: Effect of the silencing of Gli1 using siRNA was assessed with immunofluores-
cence staining. The cells were stained with anti-Gli1 (red), snail (green), E-cadherin (green), and vimentin (green) antibodies. Nuclei were 
stained with DAPI (blue). Bars = 20 µm. B: Graphs show semi-quantified data of the percentages of positive cells stained with anti-Gli1, snail, 
E-cadherin, and vimentin as mean ± standard deviation (SD) (n = 3). *, significant difference at p < 0.001 with Ctr and NC siRNA groups. Ctr, 
control; NC siRNA, negative control siRNA.
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Discussion
Our previous findings suggested that the administration of anticancer 
drug can cause arrested root development of the molars in mice via an 
induced EMT-like phenomenon10). Here we demonstrate that low con-
centration of cisplatin promotes EMT in the HERS cells via the activa-
tion of Shh/Gli1 signaling pathway by induction of DNA damage. Our 
conclusion is supported by the following observations: (a) low concen-
tration of cisplatin (0.5 µM) induces DNA damage; however, this con-
centration does not reduce the cell viability; (b) cisplatin-induced EMT 
is examined on the basis of downregulated and up-regulated expression 
of epithelial and mesenchymal markers, respectively; (c) the cispla-
tin-treated HERS cells showed increased Shh and Gli1 expressions; (d) 
Transfection of Gli1 siRNA into the HERS cells reveals a significant 
suppression of cisplatin-induced EMT.
Low concentration of cisplatin is critical for inducing EMT in the 
HERS cells. Our results from CCK-8 assay and γH2AX staining showed 
that 0.5 µM cisplatin treatment showed no reduction of the cell viability 
and no induction of cellular senescence. By γH2AX staining, DNA 
damage was observed in HERS cells treated with 0.5 µM cisplatin, but 
those cells did not reduce the viability of them. Cisplatin is an important 
anticancer drug that kills cancer cells by damaging their DNA; the for-
mation of cisplatin-DNA adducts interferes with DNA replication and 
transcription20, 21). H2AX is a key factor in the process of repair for dam-
aged DNA and is recruited to the damaged sites. In the presence of DNA 
damage, H2AX is phosphorylated on the 139th serine residue, termed 
γH2AX. Of the methods for detecting DNA damage of the cells, such as 
neutral elution, pulse field electrophoresis, and comet assays, γH2AX 
assay is a particularly precise method22). Although nuclear γH2AX stain-
ing was found in all the cisplatin-treated cells, irrespective of cisplatin 
concentration, no reduction in cell viability was obtained only in the 
HERS cells treated with low concentration of cisplatin (0.5 µM and 1.0 
µM). Our results that 0.5 µM cisplatin treatment triggers marked EMT 
in HERS cells suggest that EMT induction may depend on the degree of 
DNA damage caused by cisplatin treatment. Activation of a DNA dam-
age response, including formation of DNA damage foci containing 
γH2AX staining at persistent DNA strand breaks is the major trigger for 
cell senescence23). HERS cells treated with 0.5 µM cisplatin maintained 
a negative reaction with SA-β-Gal staining, a marker for cellular senes-
cence, although the cells treated with other concentrations of cisplatin 
showed marked cytoplasmic staining with SA- β -Gal (data not shown). 
Therefore, the pre-senescence status of 0.5 µM cisplatin-treated cells 
could be susceptible for EMT induction in HERS cells.
In the present study, EMT induction was examined with a low con-
centration of cisplatin in addition to TGF- β treatment. TGF- β -induced 
EMT is a well-known and fundamental process in organogenesis and 
cancer progression24, 25). The HERS cells stimulated by cisplatin or TGF- 
β exhibited morphological and biochemical features of EMT; western 
blot assay showed that the expression of epithelial markers was de-
creased, while the expression of mesenchymal markers was increased, 
compared with than in controls. The exposure of the HERS cells to low 
concentration of cisplatin facilitated EMT. These findings of TGF-β-in-
duced EMT in the HERS cells are in line with those reported by a previ-
ous study13). As TGF- β-induced EMT appears to be related to the com-
pletion of root formation, chemotherapy-induced EMT may lead to the 
eruption disturbances via early closure of the apex in children undergo-
ing chemotherapy.
Western blot assay and immunofluorescence staining revealed that 
HERS cells treated with 0.5 µM cisplatin showed enhanced activity of 
the Shh signaling pathway. The Shh pathway plays an important role 
during the processes of embryonic development and tumorigenesis. In 
the present study, we first detected an increase in the protein expression 
of Shh in HERS cells treated with 0.5 µM cisplatin. With immunofluo-
rescence staining, we found that the nuclear translocation of Gli1 was 
significantly enhanced in the HERS cells exposed to cisplatin than in the 
controls. The nuclear localization and accumulation of Gli1 is essential 
for its transcriptional activity. Enhanced translocation of Gli1, a target 
of Shh, indicates the activation of the Shh signaling pathway14). These 
findings suggest that the expression of Shh/Gli1 unregulated in response 
to cisplatin treatment. In our immunocytochemical staining, the number 
of Snail-expressed cells were significantly increased in the HERS cells 
treated with cisplatin. A recent study has emphasized the crucial roles of 
the transcription factor Snail during the EMT process16). Snail is also the 
target of the Shh/Gli1 signaling pathway14). Based on these findings, we 
suggest that cisplatin-induced EMT may be partially mediated by the 
Shh/Gli1 signaling pathway.
Gene silencing of Gli1 demonstrated that the activity of Shh/Gli1 
signaling pathway can promote cisplatin-induced EMT in the HERS 
cells. Immunofluorescence assay showed that the percentages of E-cad-
herin-positive cells were decreased in cisplatin-treated cells in the pres-
ence of Gli1 siRNA than in the presence of negative control siRNA. In 
contrast, the percentages of vimentin-positive cells were increased in the 
Gli1 siRNA group. Furthermore, following the blockade of Gli1 expres-
sion by siRNA, cisplatin-treated HERS cells had lower cytoplasmic 
Snail expression. Based on these data, we proposed that the treatment 
with cisplatin activated Shh/Gli1 signaling pathway, which unregulated 
the nuclear translocation of Gli1 and in turn increased Snail expression, 
finally resulting in induction of EMT.
The present study has certain limitations, especially in terms of the 
lack of direct evidence regarding whether the blockade of Shh signaling 
can suppress the activity of the cisplatin-induced EMT. Immunocyto-
chemical assay showed that silencing of Gli1, a target of Shh signaling 
inhibited the cisplatin-induced EMT. Further studies are required to ex-
amine the vital role of Shh in the cisplatin-induced EMT using pretreat-
ment of cyclopamine18), an Shh inhibitor. In this study, most data were 
obtained via immunofluorescence staining. We believe that protein ex-
pression data must be acquired using western blotting and used in the 
experiments of silencing or blockade of genes in further studies.
Thus, our findings provide additional information about the effect of 
anticancer drugs on EMT promotion in HERS cells. We demonstrated 
that low concentrations of cisplatin promote EMT in HERS cells via the 
activation of the Shh/Gli1 signaling pathway by inducing DNA damage.
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